Promising combo for Hard-to-Treat prostate cancer hits roadblock
NCT ID NCT02555189
First seen Apr 23, 2026 · Last updated May 13, 2026 · Updated 3 times
Summary
This study looked at adding a drug called ribociclib to standard hormone therapy (enzalutamide) for men with advanced prostate cancer that had spread and stopped responding to hormone treatment. The goal was to find a safe dose and see if the combination could lower PSA levels. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.